{"success":true,"data":{"pressRelease":{"id":"18604","rtpr_id":"nGNXbLG3q5","ticker":"ADMA","exchange":"NASDAQ","all_tickers":["ADMA"],"title":"$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation","author":"Globe Newswire","published_at":"2026-05-04T10:39:00.096Z","article_body":"NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=ihWafKwwQW32pwVGv4e4Pk_4fkYD85H1gnfNKpj1qn83UCzuSzacxrO7bCdwf7bwq4S0pkTVuOfj_26ZRvK4j29tDsCeb_6XG_e7iavvzUzX6RL_rnHnOpCw7wE3TQVp3RFu8RP3wFLTuNHVeJgmHF11MgZKjKrMRpYd6BFGZ6E=)\nannounces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for\npotential violations of the federal securities laws.\n\nIf you invested in ADMA Biologics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.\n\nWhy is ADMA Biologics Being Investigated for Securities Fraud?\n\nADMA Biologics is an end-to-end commercial biopharmaceutical company focused\non manufacturing and developing specialty biologics. ADMA Biologics’\nflagship product is ASCENIV, a liquid immune globulin solution used to treat\nPrimary Humoral Immunodeficiency in adults and adolescents.\n\nBFA is investigating allegations that ADMA Biologics’ reported 20% revenue\ngrowth in 2025 was driven by a channel stuffing scheme to mask deteriorating\ndemand.\n\nWhy did ADMA Biologics’ Stock Drop?\n\nOn March 24, 2026, Culper Research, an investigative research firm, published\na report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed\nRelated Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.”\nThe report revealed, among other things, that in 2025 ADMA Biologics induced\none of its distributors to “stock excess ASCENIV by offering rebates and\nextended payment terms in order to meet order expectations.” This allegedly\nallowed ADMA Biologics to book revenue and “report[] growth that was never\nthere.” According to Culper Research, had ADMA Biologics not engaged in this\nalleged channel stuffing scheme, it would have experienced revenue declines of\n3% in 2025 instead of the reported 20% growth.\n\nThis news caused the price of ADMA Biologics stock to decline $3.96 per share,\nor 29%, over the course of two trading days, from $13.59 per share on March\n23, 2026, to $9.63 per share on March 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in ADMA Biologics, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent\nnotable successes, BFA recovered over $900 million in value from Tesla,\nInc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical\nInd. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbLG3q5","title":"$ADMA Stock Drop Alert: ADMA Biologics Stock Plummeted 29% on News of Channel Stuffing – Investors Notified to Contact BFA Law about its Investigation","author":"Globe Newswire","ticker":"ADMA","created":"2026-05-04T10:39:00.096Z","tickers":["ADMA"],"exchange":"NASDAQ","article_body":"NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=ihWafKwwQW32pwVGv4e4Pk_4fkYD85H1gnfNKpj1qn83UCzuSzacxrO7bCdwf7bwq4S0pkTVuOfj_26ZRvK4j29tDsCeb_6XG_e7iavvzUzX6RL_rnHnOpCw7wE3TQVp3RFu8RP3wFLTuNHVeJgmHF11MgZKjKrMRpYd6BFGZ6E=)\nannounces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for\npotential violations of the federal securities laws.\n\nIf you invested in ADMA Biologics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.\n\nWhy is ADMA Biologics Being Investigated for Securities Fraud?\n\nADMA Biologics is an end-to-end commercial biopharmaceutical company focused\non manufacturing and developing specialty biologics. ADMA Biologics’\nflagship product is ASCENIV, a liquid immune globulin solution used to treat\nPrimary Humoral Immunodeficiency in adults and adolescents.\n\nBFA is investigating allegations that ADMA Biologics’ reported 20% revenue\ngrowth in 2025 was driven by a channel stuffing scheme to mask deteriorating\ndemand.\n\nWhy did ADMA Biologics’ Stock Drop?\n\nOn March 24, 2026, Culper Research, an investigative research firm, published\na report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed\nRelated Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.”\nThe report revealed, among other things, that in 2025 ADMA Biologics induced\none of its distributors to “stock excess ASCENIV by offering rebates and\nextended payment terms in order to meet order expectations.” This allegedly\nallowed ADMA Biologics to book revenue and “report[] growth that was never\nthere.” According to Culper Research, had ADMA Biologics not engaged in this\nalleged channel stuffing scheme, it would have experienced revenue declines of\n3% in 2025 instead of the reported 20% growth.\n\nThis news caused the price of ADMA Biologics stock to decline $3.96 per share,\nor 29%, over the course of two trading days, from $13.59 per share on March\n23, 2026, to $9.63 per share on March 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in ADMA Biologics, you may have legal options and are\nencouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent\nnotable successes, BFA recovered over $900 million in value from Tesla,\nInc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical\nInd. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T10:39:00.126367371Z","server_sent_at_ms":1777891140126},"received_at":"2026-05-04T10:39:00.186Z","source_url":"https://www.globenewswire.com/news-release/2026/04/24/3280667/0/en/adma-legal-notification-adma-biologics-securities-class-action-investigation-ongoing-investors-with-losses-after-29-stock-drop-notified-to-contact-bfa-law.html"},"analysis":{"id":"13408","press_release_id":"18604","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced an investigation into ADMA Biologics regarding potential securities law violations tied to allegations of channel stuffing.\n\nThe firm cites a March 2026 report by Culper Research claiming ADMA's reported 20% revenue growth was artificially induced, masking a 3% decline.\n\nInvestors are encouraged to contact the firm to discuss legal options on a contingency fee basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation recycling old research -- suppress."},"keyFigures":{},"quotedText":"BFA is investigating allegations that ADMA Biologics’ reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.","namedEntities":{"people":[{"name":"Adam McCall","role":"contact"}],"products":["ASCENIV"],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"target"},{"name":"Culper Research","relationship":"third-party research firm"}],"dollarAmounts":[{"amount":"$3.96","context":"per share stock price decline"},{"amount":"$13.59","context":"stock price per share on March 23, 2026"},{"amount":"$9.63","context":"stock price per share on March 25, 2026"},{"amount":"$900 million","context":"value recovered from Tesla, Inc.’s Board of Directors"},{"amount":"$420 million","context":"value recovered from Teva Pharmaceutical Ind. Ltd."}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate solicitation referencing a prior third-party report."},"tickerRelevance":{"others":[],"primary":"ADMA"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation-recycling-old-news","sectorWeight":"biotech","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced an investigation into ADMA Biologics regarding potential securities law violations tied to allegations of channel stuffing.\n\nThe firm cites a March 2026 report by Culper Research claiming ADMA's reported 20% revenue growth was artificially induced, masking a 3% decline.\n\nInvestors are encouraged to contact the firm to discuss legal options on a contingency fee basis.","key_figures":{},"named_entities":{"people":[{"name":"Adam McCall","role":"contact"}],"products":["ASCENIV"],"companies":[{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"ADMA Biologics, Inc.","ticker":"ADMA","relationship":"target"},{"name":"Culper Research","relationship":"third-party research firm"}],"dollarAmounts":[{"amount":"$3.96","context":"per share stock price decline"},{"amount":"$13.59","context":"stock price per share on March 23, 2026"},{"amount":"$9.63","context":"stock price per share on March 25, 2026"},{"amount":"$900 million","context":"value recovered from Tesla, Inc.’s Board of Directors"},{"amount":"$420 million","context":"value recovered from Teva Pharmaceutical Ind. Ltd."}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T10:39:26.774Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation-recycling-old-news","sectorWeight":"biotech","issuerAuthored":false}},"durationMs":27216,"modelName":"glm-4.7"}}